Trials / Completed
CompletedNCT02647515
Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Ruijin Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the efficacy of intravitreal ranibizumab injection as adjuvant therapy in the treatment of postvitrectomy diabetic vitreous hemorrhage (PDVH) accompanied by neovascular glaucoma (NVG) as a means of preventing recurrent vitreous hemorrhage （VH） and optimizing postoperative intraocular pressure（IOP）control.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ranibizumab |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2014-12-01
- Completion
- 2014-12-01
- First posted
- 2016-01-06
- Last updated
- 2016-01-06
Source: ClinicalTrials.gov record NCT02647515. Inclusion in this directory is not an endorsement.